- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01526759
Fiber Longer Term Study on Energy Intake (FLiTS)
The Effect of 2 Weeks of Supplementation of a High-gelling, High-viscous Dietary Fibre on Energy Intake
Dietary fibre seems to have a relevant role in body weight management. In an acute study the investigators found that high viscous-high gelling pectin increased feelings of satiety. The objective of this study is to study the effects of 2 weeks of supplementation of high gelling-high viscous fibre or a high gelling-high viscous non-fibre control on energy intake.
The investigators do this by measuring the difference in ad libitum energy intake after 15 days of pectin or 15 days of control supplements. The investigators will further measure differences in 24h feelings of satiety, fasting blood glucose and insulin, fermentation and composition of microbiota.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Wageningen, Niederlande, 7002HD
- Wageningen University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age: 18-30 year
- BMI: 18.5-25 kg/m2
- Healthy: as judged by the participant
- H2 producer
Exclusion Criteria:
- Weight loss or weight gain of more than 5 kg during the last 2 months
- Using an energy restricted diet during the last 2 months
- Lack of appetite for any reason
- Restrained eater
- Smoking
- Heavy alcohol use: >5 drinks/day
- Reported stomach or bowel diseases or disorders (e.g. irritable bowel syndrome)
- Reported diabetes
- Reported thyroid disease or any other endocrine disorder
- Using medication other than birth control, paracetamol, aspirin, hey fever and asthma
- Antibiotic use <2 months before the study
- Reported intolerance, allergy, or not liking of the research foods
- Vegetarian
- Current dietary fibre supplementation
- Fasting glucose levels >5.8 mmol/l
- Experienced any problems with drawing blood in the past
- Thesis students or employees of the division of Human Nutrition
- Volunteers who participated in the ProVe study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: pectin
10 gram high gelling-high viscous fiber, added to a drink
|
15 days 1 daily consumption of a drink with 10g pectin added
|
Placebo-Komparator: control
10g gelatin, added to a drink
|
15 days 1 daily consumption of a drink with 10g gelatin added
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Energy intake
Zeitfenster: change from placebo after 2 weeks
|
after 14 days of both intervention and placebo supplements ad libitum energy intake is measured for 3 days in a row.
The change in energy intake will be calculated.
|
change from placebo after 2 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
satiety
Zeitfenster: change from placebo after 1 day and 15 days
|
at day 1 and after 15 days of both supplement and placebo intake satiety is measured hourly over 1 day at waking hours.
The change in satiety will be calculated.
|
change from placebo after 1 day and 15 days
|
fasting glucose
Zeitfenster: change from placebo after day 0, 1 and 15
|
at day 0, 1 and day 15 of supplementation period fasting glucose is measured
|
change from placebo after day 0, 1 and 15
|
fasting insulin
Zeitfenster: change from placebo after day 0, 1 and 15
|
at day 0, 1 and day 15 of supplementation period fasting insulin is measured
|
change from placebo after day 0, 1 and 15
|
fasting leptin
Zeitfenster: change from placebo after day 0, 1 and 15
|
at day 0, 1 and day 15 of supplementation period fasting leptin is measured
|
change from placebo after day 0, 1 and 15
|
hydrogen in breath
Zeitfenster: change from placebo after day 2 and 15
|
at day 2 and at day 15 hydrogen is measured hourly over 1 day at waking hours
|
change from placebo after day 2 and 15
|
energy intake
Zeitfenster: change from placebo after day 0 and 1
|
before supplement intake and after 1 day of supplement 1-day ad libitum energy intake is measured.
The change in energy intake will be calculated.
|
change from placebo after day 0 and 1
|
body weight
Zeitfenster: change from placebo after day 0,1,2,14,15, 16 and 17
|
Each day the subject reports to the research center, body weight is measured.
The change in body weight compared to placebo will be calculated.
|
change from placebo after day 0,1,2,14,15, 16 and 17
|
adverse events
Zeitfenster: daily from day 0 to day 16
|
participants will be asked to register adverse events daily in a diary.
They are also asked to report ae's to the researchers.
number and type of AEs after fibre supplements will be compared to number and type of AEs after placebo supplements
|
daily from day 0 to day 16
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Edith Feskens, Prof, Wageningen University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- NL38515.081.11
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur LM pectin (10%)
-
Kangbuk Samsung HospitalAbgeschlossenMyomKorea, Republik von
-
LaNova Medicines Development Co., Ltd.Shanghai Zhongshan Hospital; First Affiliated Hospital of Zhejiang University; Sir Run Run Shaw Hospital und andere MitarbeiterBeendetFortgeschrittener solider TumorChina
-
Henan Cancer HospitalRekrutierungNSCLC | Hirnmetastasen | Leptomeningeale MetastasenChina
-
LaNova Medicines LimitedRekrutierungFortgeschrittener solider TumorVereinigte Staaten
-
LaNova Medicines Zhejiang Co., Ltd.Aktiv, nicht rekrutierendFortgeschrittener solider TumorChina
-
LaNova Medicines LimitedRekrutierungFortgeschrittener solider TumorChina
-
LaNova Medicines LimitedBeendetFortgeschrittene solide TumorenVereinigte Staaten
-
LaNova Australia Pty LimitedBeendetFortgeschrittener solider TumorAustralien
-
LaNova Medicines LimitedBeendetFortgeschrittene TumorenChina
-
Ganin Fertility CenterAbgeschlossenUnfruchtbarkeit | Embryonale EntwicklungÄgypten